Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26561269 | 0.88 | MMP13 (0.66) | MMP1SMN1; SMN2MAPK14KDM4EALDH1A1 | |
| SCHEMBL3961994 | 0.87 | GAA (0.59) | SMN1; SMN2HPGDKDM4EALDH1A1POLB | |
| SCHEMBL1222283 | 0.87 | SMN1; SMN2 (0.65) | MMP1SMN1; SMN2HPGDMAPK14KDM4E | |
| SCHEMBL29035428 | 0.86 | SMN1; SMN2 (0.64) | MMP1SMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL19149894 | 0.86 | MMP1 (0.70) | MMP1SMN1; SMN2HPGDMAPK14KDM4E | |
| SCHEMBL1222467 | 0.85 | MMP1 (0.74) | MMP1SMN1; SMN2HPGDMAPK14KDM4E | |
| Hydrochloric Acid SCHEMBL9331679 | 0.85 | GAA (0.57) | SMN1; SMN2HPGDKDM4EALDH1A1POLB | |
| SCHEMBL25365692 | 0.85 | MMP13 (0.58) | MMP1SMN1; SMN2HPGDMAPK14ALDH1A1 | |
| SCHEMBL25365642 | 0.85 | MAPK14 (0.61) | MMP1SMN1; SMN2HPGDMAPK14KDM4E | |
| SCHEMBL8947242 | 0.85 | KMT2A (0.67) | SMN1; SMN2KDM4EALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113795249-A | Pharmaceutical compounds for the treatment of complement-mediated disorders | 艾其林医药公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2020198062-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-RE35281-E | ANTIDIABETIC AGENTS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0388967-B1 | Aldose reductase inhibitor | WAKAMOTO PHARMA CO LTD (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5055481-A | Alleviate diabetic complications | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0388967-A1 | Aldose reductase inhibitor | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | MMP1 4417/4885SMN1; SMN2 659/4885HPGD 2001/4885 |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | MMP1 4417/4885SMN1; SMN2 659/4885HPGD 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.